Phenotypic Age Acceleration (PhenoAgeAccel) for Joint Prediction of Disease Risk, Mortality Risk, Life Expectancy, and Disease-Free Healthspan in Major Chronic Diseases

NCT07595094 | Recruiting DMC

• 1 other identifier: IIT-O-2024-136
• Study Type: observational
• Target: 2,000,000
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to learn about the ability of Phenotypic Age Acceleration (PhenoAgeAccel) to predict four key health outcomes in Chinese people with or at risk of major chronic diseases: the risk of developing new chronic diseases, the risk of dying, life expectancy, and disease-free healthspan. The main questions this study aims to answer are:

• Does higher PhenoAgeAccel increase the risk of developing major chronic diseases (including diabetes, dementia, cancer, and chronic respiratory diseases) in Chinese adults?
• Does higher PhenoAgeAccel increase the risk of death from all causes in Chinese adults?
• How do life expectancy and disease-free healthspan differ between people with high versus low PhenoAgeAccel? Who can take part in this study? Adults aged 35 or above years old who receive routine care at participating hospitals in China, have complete routine blood test data available, and have provided consent to use their health information for research purposes. What will participants go through? Participants will receive their usual medical care as they normally would. No new treatments, tests, or procedures will be performed specifically for this study. We will collect data from their medical records, including blood test results used to calculate PhenoAgeAccel, diagnoses of new diseases, and dates of death. What are the potential benefits? Participants will not receive direct personal benefits from taking part in this study. However, the information learned may help us better understand biological aging and improve future risk assessment and health management for people with chronic diseases. Is this study safe? Yes. This is an observational study that does not involve any new drugs, devices, or invasive procedures. All data used in the study will be de-identified and kept strictly confidential to protect participants' privacy.

Conditions

Biological Aging Marker; Mortality Risk Prediction; Life Expectancy; Phenotypic Age Acceleration; Disease Risk Prediction; Disease-Free Healthspan; Chinese Population; Observational Cohort Study

Outcome Measures

Primary Outcomes (2)

• Incidence of Major Chronic Diseases

  Composite incidence of new-onset major chronic diseases, including type 2 diabetes, dementia, cancer, and chronic respiratory diseases, defined by ICD-10 codes from electronic medical records.

  Baseline through study completion, average 10 years

• All-Cause Mortality

  All-cause mortality, defined as death from any cause, identified through linkage with death registration databases.

  Baseline through study completion, average 10 years

Secondary Outcomes (2)

• Life Expectancy

  Baseline through study completion, average 10 years

• Disease-Free Healthspan

  Baseline through study completion, average 10 years

Study Arms (3)

Non-accelerated PhenoAge Group

Participants with normal biological aging, defined as Phenotypic Age Acceleration ≤ 0. No study-specific intervention is administered; all participants receive routine clinical care as usual.

Other: No Intervention (Observational Study)

Mildly Accelerated PhenoAge Group

Participants with mild biological aging acceleration, defined as 0 \< Phenotypic Age Acceleration \< median. No study-specific intervention is administered; all participants receive routine clinical care as usual.

Other: No Intervention (Observational Study)

Severely Accelerated PhenoAge Group

Participants with severe biological aging acceleration, defined as Phenotypic Age Acceleration ≥ median. No study-specific intervention is administered; all participants receive routine clinical care as usual.

Other: No Intervention (Observational Study)

Interventions

No Intervention (Observational Study) OTHER

This is an observational study with no study-specific intervention. All participants receive their routine standard medical care as usual. No new drugs, devices, procedures, or behavioral modifications are assigned as part of this research.

Mildly Accelerated PhenoAge Group; Non-accelerated PhenoAge Group; Severely Accelerated PhenoAge Group

Eligibility Criteria

• Age: 35 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of Chinese adults aged 35-73 years from multicenter clinical cohorts in northern and southern China, with complete routine blood test data available at baseline. All participants are patients receiving routine care at collaborating hospitals. Data are prospectively collected via electronic medical records to analyze the association between Phenotypic Age Acceleration and major chronic disease and mortality outcomes.

You may qualify if:

• Adults aged 35-73 years old. Complete routine blood test data available at baseline to calculate Phenotypic -Age (including albumin, alkaline phosphatase, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean corpuscular volume, red cell distribution width, and white blood cell count).
• Complete demographic and clinical data (e.g., sex, BMI, comorbidities) available at baseline.
• Consent to use routine medical data for research follow-up analysis.

You may not qualify if:

• Presence of end-stage diseases (e.g., end-stage liver/renal failure) other than the major chronic diseases of interest at baseline.
• Key baseline data missing, making Phenotypic Age calculation impossible. Incomplete follow-up information or inability to confirm outcomes (e.g., death, disease onset) via database linkage.
• Refusal to participate in the study or withdrawal of informed consent.

Sponsors & Collaborators

• Second Affiliated Hospital of Nanchang University: lead

Study Sites (1)

Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China

RECRUITING

MeSH Terms

Interventions

Observation

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Central Study Contacts

Xi-jian Dai, Doctor

CONTACT

13755756959; daixjdoctor@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 8, 2026
• First Posted: May 19, 2026
• Study Start: June 1, 2006
• Primary Completion (Estimated): June 1, 2030
• Study Completion (Estimated): June 30, 2030
• Last Updated: May 19, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)